Statins in Intracerebral Hemorrhage

Current Atherosclerosis Reports

Volumn 17, Issue 8, 2015, Pages

  Lauer, Arne ^a   Greenberg, Steven M ^a   Gurol, M Edip ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Brain bleed; CAA; Cerebral amyloid angiopathy; Cholesterol; Deep hypertensive hemorrhage; Hypercholesterolemia; Intracerebral hemorrhage; LDL; Low density lipoprotein; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY PREVENTION; RECURRENCE RISK; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM; CEREBRAL HEMORRHAGE; CLINICAL STUDY; RISK FACTOR; TREATMENT OUTCOME;

CEREBRAL HEMORRHAGE; CLINICAL STUDIES AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84934903045     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-015-0526-5     Document Type: Review

References (64)

1. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke J Cereb Circ. 1997;28:946–50.
2. Amarenco P, Labreuche J, Lavallée P, Touboul P-J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke J Cereb Circ. 2004;35:2902–9.
3. Mihos CG, Pineda AM, Santana O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res Off J Ital Pharmacol Soc. 2014;88:12–9.
4. Willey JZ, Elkind MSV. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol. 2010;67:1062–7.
5. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
6. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.
7. Goldstein LB, Amarenco P, Szarek M, Callahan A, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology. 2008;70:2364–70.
8. Stone NJ, Robinson JG, Lichtenstein AH, Bairey M, Noel C, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–934.
9. Feigin VL, Lawes CMM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355–69.
10. van Asch CJJ, Luitse MJA, Rinkel GJE, van der Tweel I, Algra A, Klijn CJM. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167–76.
11. Poon MTC, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014;85:660–7.
12. Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, Csiba L, et al. European stroke organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke Off J Int Stroke Soc. 2014;9:840–55.
13. Béjot Y, Cordonnier C, Durier J, Aboa-Eboulé C, Rouaud O, Giroud M. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain. 2013;136:658–64.
14. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373:1632–44.
15. Weimar C, Benemann J, Terborg C, Walter U, Weber R, Diener H-C. Recurrent stroke after lobar and deep intracerebral hemorrhage: a hospital-based cohort study. Cerebrovasc Dis (Basel, Switz). 2011;32:283–8.
16. Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009;40:394–9.
17. Pezzini A, Padovani A. Cerebral amyloid angiopathy-related hemorrhages. Neurol Sci. 2008;29:260–3.
18. Gurol ME, Dierksen G, Betensky R, Gidicsin C, Halpin A, Becker A, et al. Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology. 2012;79:320–6.
19. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537–9.
20. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74:1346–50.
21. O’Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000;342:240–5.
22. Zhang R, Wang X, Tang Z, Liu J, Yang S, Zhang Y, et al. Apolipoprotein E gene polymorphism and the risk of intracerebral hemorrhage: a meta-analysis of epidemiologic studies. Lipids Health Dis. 2014;13:47.
23. van Etten ES, Auriel E, Haley KE, Ayres AM, Vashkevich A, Schwab KM, et al. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. Stroke. 2014;45:2280–5. A large follow-up cohort study comparing the risk of ICH in subjects with incidentally found lobar microbleeds to patients with classical presentation of CAA-related lobar ICH. No significant difference between baseline imaging/genetic characteristics and no significant difference in the risk of ICH on follow up was found, suggesting that patients with multiple lobar microbleeds without other underlying etiology might have relatively severe CAA.
24. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology. 2001;56:773–7.
25. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904–10.
26. Leppälä JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke. 1999;30:2535–40.
27. Ebrahim S, Sung J, Song Y-M, Ferrer RL, Lawlor DA, Davey Smith G. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ (Clin Res ed). 2006;333:22.
28. Mustanoja S, Strbian D, Putaala J, Meretoja A, Curtze S, Haapaniemi E, et al. Association of prestroke statin use and lipid levels with outcome of intracerebral hemorrhage. Stroke. 2013;44:2330–2.
29. Konishi M, Iso H, Komachi Y, Iida M, Shimamoto T, Jacobs DR, et al. Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. Akita Pathol Study Stroke J Cereb Circ. 1993;24:954–64.
30. Lee J-G, Koh SJ, Yoo SY, Yu JR, Lee SA, Koh G, et al. Characteristics of subjects with very low serum low-density lipoprotein cholesterol and the risk for intracerebral hemorrhage. Korean J Intern Med. 2012;27:317–26.
31. Hackam DG, Austin PC, Huang A, Juurlink DN, Mamdani MM, Paterson JM, et al. Statins and intracerebral hemorrhage: a retrospective cohort study. Arch Neurol. 2012;69:39–45.
32. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43:2149–56.
33. Amarenco P, Benavente O, Goldstein LB, Callahan A, Sillesen H, Hennerici MG, et al. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40:1405–9.
34. Woo D, Deka R, Falcone GJ, Flaherty ML, Haverbusch M, Martini SR, et al. Apolipoprotein E, statins, and risk of intracerebral hemorrhage. Stroke. 2013;44:3013–7.
35. Westover MB, Bianchi MT, Eckman MH, Greenberg SM. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol. 2011;68:573–9.
36. Haussen DC, Henninger N, Kumar S, Selim M. Statin use and microbleeds in patients with spontaneous intracerebral hemorrhage. Stroke. 2012;43:2677–81.
37. Romero JR, Preis SR, Beiser A, DeCarli C, Viswanathan A, Martinez-Ramirez S, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham heart study. Stroke. 2014;45:1492–4.
38. Lee S-H, Bae H-J, Yoon B-W, Kim H, Kim D-E, Roh J-K. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions. Stroke. 2002;33:2845–9.
39. Ricard G, Garant M-P, Carrier N, Leblanc N, Boulanger J-M. Statins may increase intracerebral hemorrhage volume. Can J Neurol Sci. 2010;37:791–6.
40. Morgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly ES, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2010;41:2108–29.
41. Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Doi M, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki prefectural health study. Circulation. 2009;119:2136–45.
42. Violi F, Calvieri C, Ferro D, Pignatelli P. Statins as antithrombotic drugs. Circulation. 2013;127:251–7.
43. Glynn RJ, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851–61.
44. Scheitz JF, Seiffge DJ, Tütüncü S, Gensicke H, Audebert HJ, Bonati LH, et al. Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke. Stroke. 2014;45:509–14.
45. Eichel R, Khoury ST, Ben-Hur T, Keidar M, Paniri R, Leker RR. Prior use of statins and outcome in patients with intracerebral haemorrhage. Eur J Neurol Off J Eur Fed Neurol Soc. 2010;17:78–83.
46. Lei C, Wu B, Liu M, Chen Y. Association between statin use and intracerebral hemorrhage: a systematic review and meta-analysis. Eur J Neurol Off J Eur Fed Neurol Soc. 2014;21:192–8.
47. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg. 2004;101:104–7.
48. Chun H-J, Kim DW, Yi H-J, Kim YS, Kim EH, Hwang SJ, et al. Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiology. 2012;33:289–96.
49. Yang D, Knight RA, Han Y, Karki K, Zhang J, Ding C, et al. Vascular recovery promoted by atorvastatin and simvastatin after experimental intracerebral hemorrhage: magnetic resonance imaging and histological study. J Neurosurg. 2011;114:1135–42.
50. Yang D, Knight RA, Han Y, Karki K, Zhang J, Chopp M, et al. Statins protect the blood brain barrier acutely after experimental intracerebral hemorrhage. J Behav Brain Sci. 2013;3:100–6.
51. Yang D, Zhang J, Han Y, James E, Chopp M, Seyfried DM. Acute statin treatment improves recovery after experimental intracerebral hemorrhage. World J Neurosci. 2013;3:69–75.
52. Indraswari F, Wang H, Lei B, James ML, Kernagis D, Warner DS, et al. Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. J Neurotrauma. 2012;29:1388–400.
53. Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Carhuapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care. 2008;8:6–12.
54. Naval NS, Abdelhak TA, Urrunaga N, Zeballos P, Mirski MA, Carhuapoma JR. An association of prior statin use with decreased perihematomal edema. Neurocrit Care. 2008;8:13–8.
55. Gomis M, Ois A, Rodríguez-Campello A, Cuadrado-Godia E, Jiménez-Conde J, Subirana I, et al. Outcome of intracerebral haemorrhage patients pre-treated with statins. Eur J Neurol Off J Eur Fed Neurol Soc. 2010;17:443–8.
56. Leker RR, Khoury ST, Rafaeli G, Shwartz R, Eichel R, Tanne D. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the national acute stroke Israeli surveys (NASIS). Stroke. 2009;40:2581–4.
57. FitzMaurice E, Wendell L, Snider R, Schwab K, Chanderraj R, Kinnecom C, et al. Effect of statins on intracerebral hemorrhage outcome and recurrence. Stroke. 2008;39:2151–4.
58. Biffi A, Devan WJ, Anderson CD, Ayres AM, Schwab K, Cortellini L, et al. Statin use and outcome after intracerebral hemorrhage: case–control study and meta-analysis. Neurology. 2011;76:1581–8.
59. Pan Y-S, Jing J, Wang Y-L, Zhao X-Q, Song B, Wang W-J, et al. Use of statin during hospitalization improves the outcome after intracerebral hemorrhage. CNS Neurosci Ther. 2014;20:548–55.
60. Cubeddu LX, Seamon MJ. Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy. 2006;26:1288–96.
61. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446–52.
62. Blanco M, Nombela F, Castellanos M, Rodriguez-Yáñez M, García-Gil M, Leira R, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69:904–10.
63. Flint AC, Conell C, Rao VA, Klingman JG, Sidney S, Johnston SC, et al. Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition. JAMA Neurol. 2014;71:1364–71.
64. Dowlatshahi D, Demchuk AM, Fang J, Kapral MK, Sharma M, Smith EE. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke. 2012;43:1518–23. One of the stronger articles on the association between pre-ICH statin use and outcomes. Statin discontinuation was still associated with poor outcomes after adjusting for stroke severity but this relationship was no longer significant after excluding patients treated palliatively. A well-designed study that also highlights one of the biggest difficulties of ICH outcomes research.